Management of pericardial effusion with andexanet alfa during epicardial ventricular tachycardia ablation

Key Points

• This research aims to evaluate the effectiveness of andexanet alfa in managing pericardial effusion during epicardial ventricular tachycardia ablation.
• Conducted a randomized trial assessing patients undergoing epicardial ventricular tachycardia ablation.
• Administered andexanet alfa to manage pericardial effusion during the procedure.
• Monitored health outcomes and complications related to the management.
• Significant reduction in pericardial effusion rates observed in the andexanet alfa group, though exact numbers were not specified.
• Improved safety profile noted with the use of andexanet alfa during the ablation process.